Fate Therapeutics to present CAR T-cell portfolio at ACR Convergence 2026
Fate Therapeutics says it has been selected for four presentations highlighting its off-the-shelf CAR T-cell portfolio in autoimmune disease at ACR Convergence 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
FATE - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026